Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab vs Nivolumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIa Squamous NSCLC
NCT07398937Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in squamous cell carcinoma of the lung (SCCL), sponsored by Fudan University. Started Feb 2026; status: recruiting.
02
Drugs
serplulimab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07398937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07398937.